Returns on this Medicare Advantage insurer depend heavily on when you bought in. Humana (NYSE:HUM) trades at $380.00 and is up 49.5% this year. Someone who put $1,000 in three years ago has about $800 today, after a 19.96% decline on adjusted prices.
Medicare Advantage Costs Broke the Old PlaybookMost of Humana’s business is Medicare Advantage, which means private plans for seniors. Those plans depend on CMS benchmark funding, risk-adjustment models, and Star Ratings quality bonuses. Utilization costs climbed, Star Ratings were cut, and the v28 risk model was phased in. Adjusted EPS came in at $17.14 for 2025, and management’s first 2026 guidance called for at least $9.00 because of the Star Ratings headwind. Shares sat at $177.99 when those results came out, near a 52-week low.
Membership Growth and Better Stars Fueled 2026Members kept signing up: individual Medicare Advantage enrollment is up 23% so far this year, and CenterWell Senior Primary Care grew 30% to about 638,000 patients. Third-quarter revenue rose 26.05% to $41.155 billion, and management raised full-year adjusted EPS guidance to at least $9.50. Bonus Year 2028 Star Ratings came in at 4.17. The CEO put it simply: “We have just one headline today, and that is that we are in a good place.”
Your $1,000 Doubled in a Decade but Still Trailed the MarketAll returns below run through the November 19 close.
1-Year Return
5-Year Return
10-Year Return
Your result depends on when you got in. A one-year buyer captured the full rebound. A five-year holder lost money while the index climbed. Even the 10-year doubling fell well short of the S&P 500. Volatility persists: shares fell 14.35% in the past week alone.
December 10 Could Decide Humana’s Next MoveThe bull case strengthens if the 2027 bids lift margins toward the 3% pre-tax target for 2028. A one-time Stars tailwind is also expected that year. The bear case strengthens if costs outrun pricing. Management expects a 2027 core cost trend of 8% to 9%, and the Part D trend is expected to rise 14% to 15%. There’s also a securities fraud lawsuit and Medicaid procurement risk in Texas and Georgia.
The setup looks cautiously positive heading into the December 10 investor update. Humana has shown it can grow. What it still has to show is that it can grow profitably for several years in a row.